» Articles » PMID: 38237211

Multi-omics Comprehensive Analyses of Programmed Cell Death Patterns to Regulate the Immune Characteristics of Head and Neck Squamous Cell Carcinoma

Overview
Journal Transl Oncol
Specialty Oncology
Date 2024 Jan 18
PMID 38237211
Authors
Affiliations
Soon will be listed here.
Abstract

Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous cancer with high morbidity and mortality. Triggering the programmed cell death (PCD) to enhance the anti-tumor therapies is being applied in multiple cancers. However, the limited understanding of genetic heterogeneity in HNSCC severely hampers the clinical efficacy. We systematically analyzed 14 types of PCD in HNSCC from The Cancer Genome Atlas (TCGA). We utilized ssGSEA to calculate the PCD scores and classify patients into two clusters. Subsequently, we displayed the genomic alteration landscape to unravel the significant differences in copy number alterations and gene mutations. Furthermore, we calculated the IC50 values of targeted drugs to predict the differences in sensitivity. To identify the immune-related prognostic types, we comprehensively estimated the relationship between immune indicators and all prognostic PCD in three datasets (TCGA, GSE65858, GSE41613). Finally, 7 regulators were filtered. Subsequently, we integrated 10 machine learning algorithms and 101 algorithm combinations to test the clinical predictive efficacy. Using WGCNA as a basis, we built a weighted co-expression network to identify modules involved in the immune landscape with different colors. Meanwhile, our results indicated that blue and red modules containing crucial regulators closely related to the CD4+, CD8+ T cells, TMB or PD-L1. FCGR2A from blue module, CSF2, INHBA, and THBS1 from the red module were determined. After verifying in vivo experiments, FCGR2A was identified as hub gene. In conclusion, our findings suggest a potential role of PCD in HNSCC, offering new insights into effective immunotherapy and anti-tumor therapies in HNSCC.

References
1.
Feldser D, Kostova K, Winslow M, Taylor S, Cashman C, Whittaker C . Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature. 2010; 468(7323):572-5. PMC: 3003305. DOI: 10.1038/nature09535. View

2.
Raudenska M, Balvan J, Masarik M . Cell death in head and neck cancer pathogenesis and treatment. Cell Death Dis. 2021; 12(2):192. PMC: 7893032. DOI: 10.1038/s41419-021-03474-5. View

3.
Kumagai S, Togashi Y, Kamada T, Sugiyama E, Nishinakamura H, Takeuchi Y . The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol. 2020; 21(11):1346-1358. DOI: 10.1038/s41590-020-0769-3. View

4.
He J, Yu L, Qiao Z, Yu B, Liu Y, Ren H . Genetic polymorphisms of FCGR2A, ORAI1 and CD40 are associated with risk of lung cancer. Eur J Cancer Prev. 2021; 31(1):7-13. DOI: 10.1097/CEJ.0000000000000671. View

5.
Hernandez G, Perera R . Autophagy in cancer cell remodeling and quality control. Mol Cell. 2022; 82(8):1514-1527. PMC: 9119670. DOI: 10.1016/j.molcel.2022.03.023. View